Contact Us
800-658-2849
Vaccines Redefined
This block contains code to allow dead links in the navigation to function properly. This block will not be visible on the live site.
DO NOT DELETE
Home
About Us
Business Strategy
Partnerships
Board of Directors
Product Portfolio
Overview
Pipeline
Cancer Treatments
Clinical Experience
Technology
Technology Overview
Alphavaccine Platform
Alphavaccine Applications
Alphavaccine Tour
Intellectual Property
Scientific References
Presentations
Investors
Press Releases
Press Release Archive
Alphavax Fact Sheet
Contact Us
Investors
Press Release Archive
08/09/2010
AlphaVax’s Vector System Shows Potential for Cancer Immunotherapy click here >>
01/19/2010
AlphaVax Advances Filovirus Biodefense Vaccines click here >>
09/01/2009
AlphaVax Progresses H1N1 Influenza Vaccine click here >>
07/17/2009
AlphaVax Announces Results from Initial Testing of its H1N1 (Swine) Influenza Vaccine click here >>
05/28/2009
2009 IBC Meeting click here >>
05/14/2009
AlphaVax Announces Phase I/II Study of Active Cancer Immunotherapy click here >>
05/13/2009
AlphaVax Announces Promising Results in Melanoma Studies click here >>
02/16/2009
AlphaVax Announces New Vice President of Regulatory, Quality and Clinical Operations click here >>
12/29/2008
Novartis enters into exclusive agreement with AlphaVax for novel CMV vaccine candidate click here >>
10/29/2008
AlphaVax Presents Results from CMV Phase 1 Trial click here >>
07/21/2008
AlphaVax Announces Initiation of Chlamydia Vaccine Program click here >>
06/06/2008
AlphaVax Continues to Expand the Use of its Vaccine Platform click here >>
04/17/2008
AlphaVax Announces Initial Analysis of Data from CMV Phase 1 Clinical Trial click here >>
01/30/2008
AlphaVax Announces New CMV Advisory Board click here >>
10/31/2007
AlphaVax Announces Results from Phase 1 Influenza Vaccine Clinical Trial click here >>
07/30/2007
AlphaVax Announces Interim Results from Phase 1 Influenza Vaccine Clinical Trial click here >>
07/10/2007
AlphaVax Announces $3.6M Award to Develop New Adjuvant Technologies for Vaccines click here >>
04/11/2007
AlphaVax begins Clinical Trials with Vaccines for CMV and FLU click here >>
03/13/2007
In The Pipeline click here >> 02/19/2007 New Data Support AlphaVax's Vaccine for CMV click here >>
02/02/2007
AlphaVax Announces the Closing of its E Series Investment Offering click here >>
01/29/2007
AlphaVax Announces Clinical Trials for Influenza and CMV click here >>
10/11/2006
Parents of EEE victim raising money for disease research click here >>
09/06/2006
AlphaVax Announces Phase 1 Clinical Trial Results click here >>
07/26/2006
AlphaVax Granted Key Vaccine Manufacturing Patent in US click here >>
05/10/2006
Three NCBIO members serving on National BIO Committees click here >>
04/05/2006
Peter Young to Testify on BioShield click here >>
11/11/2005
The Triangle’s Fastest Growing Private Biotech Company click here >>
10/21/2005
Alphavax Announces Support of Senator Richard Burr's Legislation click here >>
10/19/2005
Alphavax Announces $3.3 Million Grant Award to Develop A Smallpox Vaccine click here >>
06/03/2005
AlphaVax Announces New Lease for Vaccine Manufacturing Operations click here >>
05/01/2005
Peter Young elected Chair of NCBIO click here >>
04/10/2005
AlphaVax Annouces NIH Award for Influenza Vaccine click here >>
02/06/2005
Gene Vaccine Protects Mice Against Development of Her2/neu Breast Cancer click here >>
11/17/2004
AlphaVax Annouces $4.8m Award for a SARS Vaccine click here >>
06/04/2004
AlphaVax Annouces New Vice President of Development click here >>
03/25/2004
AlphaVax Annouces New Manufacturing Initiative click here >>
11/19/2003
AlphaVax Names Jonathan Smith Chief Scientific Officer click here >>
10/21/2003
AlphaVax Annouces New $16.8 Million NIH Award click here >>
09/05/2003
AlphaVax Receives Two NIH Biodefense Grants click here >>
08/22/2003
AlphaVax Begins Human Clinical Trials of Novel Vaccine Technology click here >>
07/12/2003
Progenics and Cytogen Develop Novel Prostate Cancer Vaccine with AlphaVax click here >>
06/26/2003
AlphaVax Hires New Medical Director click here >>
05/15/2003
AlphaVax Annouces New Head of Discovery and New Facility click here >>
04/03/2002
AlphaVax Annouces $11 million in Series C click here >>
03/04/2002
AlphaVax signs Manufacturing Agreement click here >>
02/28/2001
AlphaVax announces $8.2 million in Series B click here >>
02/03/2001
Glaxo Wellcome VP, Peter F. Young, named as President of AlphaVax click here >>
11/19/2000
International AIDS Vaccine Initiative Announces Major Research Partnership with AlphaVax click here >>
View on Mobile